MitoQ

Mitoquinone mesylate (MitoQ) is a mitochondria-targeted antioxidant composed of a ubiquinone moiety covalently linked via a ten-carbon alkyl chain to a triphenylphosphonium (TPP+) cation, enabling rapid permeation of lipid bilayers and accumulation within the mitochondrial matrix at concentrations up to several hundred-fold above extracellular levels, driven by the large negative mitochondrial membrane potential (approximately negative 150 to negative 180 millivolts). The compound was developed in the 1990s by Robin Smith and Michael Murphy at the University of Otago, New Zealand, as an approach to overcoming the failure of conventional untargeted antioxidants (including native coenzyme Q10) to achieve therapeutically meaningful concentrations within mitochondria, the principal intracellular source of reactive oxygen species (ROS). Within the mitochondrion, MitoQ adsorbs to the matrix-facing leaflet of the inner mitochondrial membrane, where the ubiquinone head group is reduced to the active antioxidant ubiquinol form by complex II (succinate:ubiquinone oxidoreductase) of the electron transport chain. The ubiquinol form scavenges superoxide, hydroxyl radicals, and peroxyl radicals, preventing lipid peroxidation of cardiolipin and other mitochondrial membrane phospholipids. Following oxidation during radical quenching, the resulting ubiquinone is re-reduced by complex II, establishing a catalytic antioxidant cycle that permits repeated radical neutralization from a single molecule. This recycling mechanism distinguishes MitoQ from stoichiometric antioxidants such as alpha-tocopherol that are consumed in the quenching reaction. Preclinical pharmacology has demonstrated protective effects in rodent models of ischemia-reperfusion injury, diabetic nephropathy, nonalcoholic fatty liver disease, sepsis-associated organ failure, pulmonary hypertension, Alzheimer’s disease, doxorubicin-induced cardiomyopathy, cisplatin nephrotoxicity, and metabolic syndrome, with consistent reductions in mitochondrial oxidative damage markers, preservation of mitochondrial membrane potential, and attenuation of downstream inflammatory signaling through suppression of NF-kappaB activation and NLRP3 inflammasome assembly. Four completed human clinical trials define the current clinical evidence base. The Snow et al. (2010) PROTECT study, a 12-month randomized double-blind placebo-controlled trial in 128 newly diagnosed untreated Parkinson’s disease patients at 40 or 80 mg per day, found no difference between MitoQ and placebo on any measure of disease progression, establishing an important negative result for the oxidative stress hypothesis in early Parkinson’s disease. The Gane et al. (2010) phase II trial in 30 patients with chronic hepatitis C virus infection demonstrated significant decreases in serum alanine aminotransferase and aspartate aminotransferase at 40 and 80 mg per day over 28 days, without change in viral load, suggesting hepatoprotective activity through reduction of mitochondrial oxidative necroinflammation. The Rossman et al. (2018) randomized crossover trial in 20 healthy older adults (60 to 79 years) with impaired endothelial function demonstrated that 6 weeks of MitoQ at 20 mg per day produced a 42 percent improvement in brachial artery flow-mediated dilation versus placebo, with concurrent reductions in plasma oxidized low-density lipoprotein and aortic pulse wave velocity, establishing the first human evidence for mitochondria-targeted antioxidant improvement of age-related vascular dysfunction. A 2024 exploratory pilot trial (Jain et al. 2024) of MitoQ as post-exposure prophylaxis against SARS-CoV-2 infection reported reduced infection rates and symptom duration in the treatment group versus matched controls. The compound is well tolerated in human studies at doses up to 80 mg per day for 12 months, with nausea and gastrointestinal discomfort as the principal dose-limiting adverse events. MitoQ is not approved as a pharmaceutical by any regulatory authority; it is marketed globally as a dietary supplement at doses of 5 to 10 mg per day and is available as a research-grade compound from multiple chemical suppliers. This monograph reviews the chemistry, synthesis, and mitochondrial targeting mechanism of MitoQ; the comprehensive preclinical pharmacology across disease models; the complete human clinical evidence base; pharmacokinetics including the low oral bioavailability and extensive first-pass metabolism; sourcing, reconstitution, and handling; stack-interaction considerations; adverse-event signal; and a structured comparative assessment of five mitochondria-targeted antioxidant candidates (SkQ1, elamipretide, MitoTEMPO, MitoVitE, idebenone) against MitoQ on five competency standards.